COBALT advises EPhaG AS on the investment into its Moscow-listed subsidiary Pharmsynthez by US based OPKO Health Inc.

COBALT advised Estonian company EPhaG AS in connection with the 46 million Euro investment into its subsidiary, Moscow-listed pharmaceutical company Pharmsynthez OJSC by US-based OPKO Health, Inc. The deal also included an additional investment of 20 million Euros by the existing shareholder of Pharmsynthez, Russian state-owned company Rusnano. Pharmsynthez operates state-of-the-art pharmaceutical production facilities in Russia and, through its Estonian subsidiary AS Kevelt, in Estonia. The significant investment allows Pharmsynthez to broaden its already strong product base and access the US market.

COBALT team was led by partners Marina Tolmatshova and Martin Simovart and included associate Kristjan Kotkas.